Co-Diagnostics (CODX) to Release Quarterly Earnings on Tuesday

Co-Diagnostics (NASDAQ:CODX) will likely be releasing its Q4 2025 results after the market closes on Tuesday, March 31st. Analysts expect Co-Diagnostics to post earnings of ($3.90) per share and revenue of $0.1260 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:30 PM ET.

Co-Diagnostics Stock Performance

Shares of CODX opened at $1.75 on Friday. Co-Diagnostics has a 52 week low of $1.66 and a 52 week high of $46.50. The stock has a market capitalization of $3.68 million, a price-to-earnings ratio of -0.06 and a beta of 1.31. The stock has a fifty day moving average of $2.50 and a 200-day moving average of $7.56.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CODX. Maxim Group cut Co-Diagnostics from a “buy” rating to a “hold” rating in a report on Friday, January 23rd. Wall Street Zen upgraded Co-Diagnostics from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $67.50.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Virtu Financial LLC lifted its holdings in Co-Diagnostics by 393.8% during the 3rd quarter. Virtu Financial LLC now owns 126,524 shares of the company’s stock worth $44,000 after buying an additional 100,901 shares during the period. Geode Capital Management LLC increased its stake in shares of Co-Diagnostics by 40.4% in the fourth quarter. Geode Capital Management LLC now owns 449,148 shares of the company’s stock valued at $81,000 after buying an additional 129,158 shares during the period. Finally, Jane Street Group LLC raised its position in shares of Co-Diagnostics by 314.1% during the second quarter. Jane Street Group LLC now owns 166,254 shares of the company’s stock worth $47,000 after acquiring an additional 126,105 shares during the last quarter. 14.99% of the stock is owned by institutional investors.

About Co-Diagnostics

Co-Diagnostics, Inc is a molecular diagnostics company headquartered in Salt Lake City, Utah, known for its proprietary CoPrimer™ technology. Founded in 2016, the company focuses on the design, development and distribution of molecular diagnostic test kits for the detection of infectious diseases, genetic mutations and other health-relevant biomarkers. Its core platform leverages patented cooperative primers, which are engineered to enhance specificity, sensitivity and cost-effectiveness compared to conventional PCR-based assays.

Through its in-house manufacturing and global supply chain partnerships, Co-Diagnostics produces a range of real-time polymerase chain reaction (qPCR) kits, reagents and customized assay development services.